Venus Medtech acquires Cardiovalve for $300 million

Venus Medtech (Hangzhou) Inc. announced the acquisition of 100% equity interest in Cardiovalve Ltd., a transcatheter mitral and tricuspid valve treatment company, for a consideration of $300 million. The acquisition aims to expand Venus Medtech's product pipeline in mitral and tricuspid valve replacement.

“Venus Medtech will acquire 100% equity interest and corresponding equity at a consideration of $300 million, and will pay the consideration conditionally in installments subject to the completion of certain milestone events as agreed.”newswire.ca

• 1 source
• newswire.caVenus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve ReplacementVenus Medtech (Hangzhou) Inc.Dec 8, 2021

Summarized from public sources; check the original articles before acting on it.